The lung provides an attractive drug absorption target for both local and systemic disease states and is increasingly utilized for the delivery of both small molecules and biotherapeutics. Dry powder inhalers (DPIs) are often a preferred drug delivery platform due to their inherent formulation flexibility and patient convenience.
Our core particle engineering expertise is complemented with extensive formulation and process development, specialized CMC/analytical, and encapsulation capabilities to provide integrated DPI product development from concept through the clinic and commercialization.
Please note that Lonza has updated its Privacy Policy. By visiting our website or using services provided by Lonza, you are accepting the practices described in the Privacy Policy.
We also use cookies on our websites. Cookies allow us to give you the best browsing experience and help us to understand how you use our site. You can disable cookies but parts of our website may not work. Please read our updated Cookies Policy for information about which cookies we use and the information we collect. By continuing to use this website, you agree that we may store and access cookies on your device.
By clicking "I Agree", you confirm that you are above the age of 16, that you have read and understood the Privacy Policy and the Cookies Policy, and that you agree to the collection, use and processing of your Personal Information by Lonza in accordance with said policies.